Teva Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) Tops Q1 EPS by 4c, Revenues Miss; Offers FY21 EPS/Revenue Guidance
April 28, 2021 7:04 AM EDTTeva Pharma (NYSE: TEVA) reported Q1 EPS of $0.63, $0.04 better than the analyst estimate of $0.59. Revenue for the quarter came in at $3.98 billion versus the consensus estimate of $4.02 billion.
Revenues of $4.0 billionGAAP diluted EPS of $0.07Non-GAAP diluted EPS of... More